

Special Issue

Chemotherapy and Invasive Fungal Infection

Message from the Guest Editor

Patients receiving chemotherapy are at risk of developing invasive fungal infection (IFI). The epidemiology is changing with the introduction of new targeted cancer immunotherapies. New diagnostic tests have been developed in recent years and are undergoing evaluation to determine their utility in clinical practice. Antifungal resistance is increasing, indicating the importance of routine antifungal susceptibility testing, therapeutic drug monitoring and the potential for combination antifungal therapy. New antifungal agents are currently being evaluated in trials. Given the recent developments in this area, the purpose of this Special Issue is to highlight these new developments through state-of-the-art reviews and original research articles. Sincerely,

Guest Editor

Prof. Dr. C. Orla Morrissey

Department of Infectious Diseases, Alfred Health and Central Clinical School, Monash University, Melbourne, VIC, Australia

Deadline for manuscript submissions

closed (1 May 2021)



Journal of Fungi

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.4
Indexed in PubMed



mdpi.com/si/62254

Journal of Fungi
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jof@mdpi.com

mdpi.com/journal/

[jof](https://www.mdpi.com/journal/jof)





Journal of Fungi

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.4
Indexed in PubMed



mdpi.com/journal/

[jof](https://mdpi.com/journal/)



About the Journal

Message from the Editor-in-Chief

The *Journal of Fungi* (JoF, ISSN 2309-608X) is an international, peer-reviewed, scientific, open access journal that provides an advanced forum for studies related to pathogenic fungi, fungal biology, and all other aspects of fungal research. Research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. David S. Perlin

Hackensack Meridian Health Center for Discovery and Innovation, 340
Kingsland Street, Nutley, NJ 07110, USA

Author Benefits

Open Access

– free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Mycology) / CiteScore - Q1 (Ecology, Evolution, Behavior and Systematics)